MedTrace Logo

Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy

NCT07463781 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-03-13

No results posted yet for this study

Summary

This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)
  • High Grade B Cell Lymphoma
  • Primary Mediastinal B-cell Lymphoma (PMBCL)

Interventions

OTHER

Chimeric Antigen Receptor T-cells (CAR-T) therapy

Patients will be treated with CAR-T cell product as per routine clinical practice.

Sponsors & Collaborators

  • Fondazione Lorenzo Farinelli Onlus

    collaborator UNKNOWN

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Luca Castagna · A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-05-31
Completion
2029-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07463781 on ClinicalTrials.gov